Table 1.
Women (n = 338) | |||
---|---|---|---|
No VF (n = 264) | ≥ 1 VF Gr. ≥ 1 (n = 74) | P value | |
Age (years) | 62.9 ± 7.8 | 67.7 ± 8.4 | .000* |
Height (cm) | 1.6 ± 0.1 | 1.6 ± 0.1 | .295 |
Weight (kg) | 74.6 ± 14.3 | 72.7 ± 12.1 | .296 |
BMI (kg/m2) | 27.6 ± 5.0 | 27.1 ± 4.0 | .474 |
FRAX major osteoporotic fractures | 82 (31.1) | 30 (40.5) | .126 |
LS aBMD (g/cm2) | 0.93 ± 0.14 | 0.91 ± 0.17 | .388 |
FN aBMD (g/cm2) | 0.70 ± 0.11 | 0.67 ± 0.10 | .032* |
TH aBMD (g/cm2) | 0.85 ± 0.13 | 0.81 ± 0.12 | .028* |
Normal BMD | 72 (27.3) | 13 (17.6) | .113 |
Osteopenia | 135 (51.1) | 38 (51.4) | |
Osteoporosis | 57 (21.6) | 23 (31.1) | |
Previous fracture after age 50 years | 48 (18.2) | 36 (48.6) | .000* |
Parent fractured hip | 17 (6.4) | 4 (5.4) | .999 |
Current smoking | 36 (13.6) | 9 (12.2) | .741 |
Glucocorticoids | 12 (4.5) | 3 (4.1) | .999 |
Rheumatoid arthritis | 10 (3.8) | 4 (5.4) | .516 |
Secondary osteoporosis | 70 (26.5) | 21 (28.4) | .749 |
Alcohol ≥ 3 units/day | 4 (1.5) | 1 (1.4) | .999 |
History or current use of anti-osteoporosis drugs | 21 (8.0) | 19 (26.0) | .000* |
Self-reported use of anti-osteoporosis medication, n (%) | 18 (6.9) | 18 (24.7) | .000* |
Type, n (%)# | |||
Alendronic acid | 11 (61.1) | 9 (50.0) | .887 |
Risedronic acid | 5 (27.8) | 6 (33.3) | |
Zoledronic acid | 0 (0.0) | 1 (5.6) | |
Unknown | 2 (11.1) | 2 (11.1) | |
Duration (year), mean ± SD# | 4.5 ± 2.7 | 5.2 ± 4.1 | .577 |
Current, n (%)# | 3 (16.7) | 10 (55.6) | .015* |
History, n (%)# | 15 (83.3) | 8 (44.4) | |
Time since cessation of treatment (year), mean ± SD# | 2.6 ± 2.6 | 1.1 ± 2.3 | .109 |
Falls past year | 79 (30.0) | 21 (28.8) | .834 |
Variables are presented as mean ± standard deviation or number (percentage). P value < 0.05 is considered significant (*)
#In patients who have ever used anti-osteoporosis medication
VF, vertebral fracture; BMI, body mass index; LS, lumbar spine; FN, femoral neck, TH, total hip; aBMD, areal bone mineral density